Technology

Targeted Granzyme B Immunotherapy (TGI)

Our ADC platform harnesses the precision of antibodies to deliver granzyme-based cytotoxic agents directly to tumor cells, sparing healthy tissues and reducing side effects.

Targeted Granzyme B Immunotherapy (TGI) Platform

At AbBC Therapies, we are pioneering a next-generation Targeted Granzyme B Immunotherapy (TGI) platform that merges the tumor-targeting precision of antibody–drug conjugates (ADCs) with the potent, natural killing mechanism of immune effector proteins—into a single, fully biologic hybrid molecule.
This innovative construct is designed to deliver highly selective, durable tumor killing while minimizing systemic toxicity and simplifying manufacturing.

0:00 / 0:00

Mechanism and Molecular Design

Novel, Patented Antibody–Granzyme B Configuration

A fully human, catalytically active Granzyme B (GrB) protein is fused to a human synthetic antibody or antibody fragment that recognizes a tumor-specific antigen.
The resulting fusion molecule is circulating-stable and non-toxic in systemic circulation.
GrB’s prolonged serum half-life (~35 hours) enables enhanced tumor accumulation and sustained exposure at the disease site.
Upon antigen-mediated endocytosis, the conjugate is internalized and delivers GrB directly into the cytosol of the cancer cell, where it triggers apoptosis.
The modular architecture allows universal pairing of GrB with virtually any antibody or targeting ligand, providing broad adaptability across indications.

Targeted Granzyme B Platform: A Class Beyond Cytotoxic Agents

AbBC’s TGI platform introduces a fundamentally new therapeutic class—biologic Granzyme B conjugates that retain the precision of ADCs but replace chemical payloads with a natural cytotoxic enzyme.

Key advantages

Novel, Patented Antibody–Granzyme B Configuration

Fully human composition — no synthetic toxins or chemical linkers.
Mechanism of action mirrors T-cell cytotoxicity (as in CAR-T therapy) yet bypasses immune checkpoints, enabling broader and more consistent tumor killing.
IgG dimerization (~160 kDa) extends half-life and optimizes pharmacokinetics.
Internalized GrB remains catalytically active in both released and retained forms, ensuring sustained intracellular activity.
Unconjugated GrB is biologically inert to normal cells, reinforcing its favorable safety profile.
Manufacturing simplicity — the GrB–antibody conjugate is produced through a standard antibody manufacturing process, without the complexities of chemical conjugation.
Demonstrated preclinical safety and efficacy: - Example: GrB–Antibody shows a maximum tolerated dose (MTD) > 500 mg/kg in mice, with a wide therapeutic index and efficacy at 40–150 mg/kg.

Mode of Action: Targeted Delivery of Granzyme B

Target Recognition — The antibody fragment selectively binds to tumor-associated antigens.
Internalization — The GrB conjugate is internalized through receptor-mediated endocytosis.
Cytosolic Release — Granzyme B enters the cytosol of the cancer cell.
Cell Death Activation — GrB triggers apoptosis through caspase cleavage, mitochondrial disruption, and DNA fragmentation, while also promoting immunogenic cell death that recruits and activates the immune system.

The AbBC TGI platform unites antibody precision, immune killing power, and biologic manufacturability into one therapeutic entity—establishing a new class of safer, scalable, and more effective targeted therapies for oncology and ophthalmology.